Enhertu (fam-trastuzumab deruxtecan-nxki), new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
The U.S. Food and Drug Administration granted accelerated approval to Enhertu…
Per informazioni
+41 (0)91 682 20 40
The U.S. Food and Drug Administration granted accelerated approval to Enhertu…